{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-015212","form_type":"8-K","ticker":"CLNN","cik":"0001822791","company_name":"Clene Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.401454+00:00","generated_at":"2026-06-02T12:42:06.502542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Clene Q1 net loss $11.1M ($0.09/shr); cash $27.9M; VISIONARY-MS data positive","bullets":["Cash, equivalents and marketable securities $27.9M at Mar 31, down from $35.0M at Dec 31, 2023; expected to fund operations into Q4 2024.","Net loss $11.1M ($0.09/shr) vs $11.8M ($0.15/shr) YoY; R&D expenses fell to $5.9M from $7.4M.","Long-term VISIONARY-MS extension: significant vision improvement (up to 38 letters, p<0.001) and cognition (SDMT +29 points, p<0.001).","Received $7.3M NIH sub-award for ALS Expanded Access Program; company advancing FDA discussions for NDA filing in H2 2024.","Peer-reviewed publication in ACS journal characterized CNM-Au8 protein corona supporting neuroprotective mechanism."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-015212","json":"https://secwatch.observer/filing/0001437749-24-015212.json","markdown":"https://secwatch.observer/filing/0001437749-24-015212.md","text":"https://secwatch.observer/filing/0001437749-24-015212.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/0001437749-24-015212-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/clnn20240202_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:42:06.502542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d7dfa56820304a3b8eb5cce31a78dc439a5c08b","claim":"Clene Inc. reported first quarter 2024 results: net income net loss of $11.1 million, EPS $0.09 per share.","evidence_excerpt":"Clene reported a net loss of $11.1 million , or $0.09 per share, for the quarter ended March 31, 2024","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1822791/000143774924015212/0001437749-24-015212-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"net loss of $11.1 million"},{"label":"EPS","value":"$0.09 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}